Scleritis in a Patient with Castleman Disease
10.3341/jkos.2018.59.8.785
- Author:
Jae Jung LEE
1
;
In Ho LEE
;
Kang Yeun PARK
;
Sung Who PARK
;
Ji Eun LEE
Author Information
1. Department of Ophthalmology, Pusan National University School of Medicine, Yangsan, Korea. jlee@pusan.ac.kr
- Publication Type:Case Report
- Keywords:
Castleman disease;
Scleritis
- MeSH:
Adult;
Anterior Chamber;
Cataract Extraction;
Corneal Edema;
Drug Therapy;
Edema;
Follow-Up Studies;
Giant Lymph Node Hyperplasia;
Humans;
Inflammation;
Intraocular Pressure;
Iridectomy;
Male;
Methotrexate;
Prognosis;
Recurrence;
Scleritis;
Slit Lamp;
Steroids;
Uveitis;
Uveitis, Anterior;
Visual Acuity
- From:Journal of the Korean Ophthalmological Society
2018;59(8):785-789
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To report a case of multicentric Castleman disease that presented with scleritis. CASE SUMMARY: A 42-year-old male presented with decreased visual acuity in the left eye. Castleman disease had been diagnosed 21 months before and treated with systemic steroids and combined chemotherapy. Best-corrected visual acuity (BCVA) of the left eye was 0.02 and the intraocular pressure was 42 mmHg. Scleral edema and corneal edema were noted using a slit lamp examination. The anterior chamber cell was 2+ according to Standardization of Uveitis Nomenclature criteria. The fundus was invisible due to the anterior segment lesion. After one month, scleritis developed in the right eye and the patient complained of ocular pain. Topical steroids and non-steroidal anti-inflammatory drugs were prescribed. Due to recurrent scleritis and anterior uveitis, cataract extraction and laser iridectomy were performed on the left eye, and systemic steroids and the antimetabolite methotrexate were started. After 9 years of follow-up, all medications were stopped and there was no recurrence of inflammation, with a BCVA of 1.0 in both eyes. CONCLUSIONS: Treatment of a patient with scleritis accompanied with Castleman disease using systemic steroids and methotrexate resulted in a good prognosis.
